REGULATION (EU) NO 536/2014 ON CLINICAL TRIALS AND VULNERABLE GROUPS

被引:0
|
作者
Marino Hernandez, Eduardo L. [1 ]
机构
[1] Univ Barcelona, Fac Farm, Dept Farm & Tecnol Farmaceut, Avda Juan 23 S-N, E-08028 Barcelona, Spain
来源
CUADERNOS DE BIOETICA | 2015年 / 26卷 / 88期
关键词
Clinical Trials; Vulnerable groups; Regulation;
D O I
暂无
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
A complete review of the normative established for clinical trials in vulnerable patient is performed. To do that, the basis is the last European norm, that is, the Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance). It is checked all related to vulnerable patients from the previous European norm. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 and the corresponding transpositions into Spanish law by Royal Decree 223/2004, of February 6, 2004, whereby clinical drug trials and Law 29/2006 of 26 July, on guarantees and regulates use rational use of medicines and health products.
引用
收藏
页码:427 / 430
页数:4
相关论文
共 50 条
  • [1] Principles of the EU Clinical Trials Regulation No 536/2014 What will change?
    Mende, Aylin
    Frech, Marion
    Riedel, Claudia
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2017, 60 (08) : 795 - 803
  • [2] An EU Comparative Analysis of the Regulation of Clinical Trials Supervisory Bodies in the Aftermath of Regulation 536/2014
    de Miguel Beriain, Inigo
    Chortara, Theodora
    Duardo-Sanchez, Aliuska
    Feeney, Oliver
    Felzmann, Heike
    Fernandez de Uzquiano, Emma
    Lievevrouw, Elisa
    Marelli, Luca
    Mattsson, Titti
    Herrmann, Janne Rothmar
    Minssen, Timo
    Pulice, Elisabetta
    Raposo, Vera Lucia
    Robienski, Jurgen
    Penasa, Simone
    Van Hoyweghen, Inc
    EUROPEAN PUBLIC LAW, 2020, 26 (02): : 307 - 329
  • [3] Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use: an overview
    Petrini, Carlo
    ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2014, 50 (04): : 317 - 321
  • [4] The European clinical trials regulation (No 536/2014): changes and challenges
    Scavone, Cristina
    di Mauro, Gabriella
    Pietropaolo, Michela
    Alfano, Roberto
    Berrino, Liberato
    Rossi, Francesco
    Tomino, Carlo
    Capuano, Annalisa
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (11) : 1027 - 1032
  • [5] Main changes in European Clinical Trials Regulation (No 536/2014)
    Tenti, E.
    Simonetti, G.
    Bochicchio, M. T.
    Martinelli, G.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2018, 11 : 99 - 101
  • [6] Grundzüge der EU-Verordnung 536/2014Was wird sich ändern?Principles of the EU Clinical Trials Regulation No 536/2014What will change?
    Aylin Mende
    Marion Frech
    Claudia Riedel
    Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2017, 60 : 795 - 803
  • [7] GCP and Quality in "Regulation (EU) 536/2014 on clinical trials on medicinal products for human use and repealing Directive 2001/20/EU
    Filibeck, Umberto
    Sanzi, Eleonora
    MICROCHEMICAL JOURNAL, 2018, 136 : 40 - 42
  • [8] The new European Regulation 536/2014 concerning clinical trials: A systematic review
    Chalkiadaki, E.
    Galanis, P.
    Lamnisos, D.
    ARCHIVES OF HELLENIC MEDICINE, 2020, 37 (01): : 106 - 115
  • [9] Vorbereitungsstand zur EU Verordnung 536/2014 in den MitgliedstaatenImplementation status of Regulation EU 536/2014 in the member states
    Elke Stahl
    Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2017, 60 (8) : 836 - 840